
Contents

<i>Preface</i>	<i>v</i>
<i>Acknowledgments</i>	<i>vii</i>
<i>Contributors</i>	<i>xiii</i>

PART I BACKGROUND

1 The Path to Oncology Drug Target Validation: An Industry Perspective	3
<i>Marta Cortés-Cros, Tobias Schmelzle, Volker M. Stucke, and Francesco Hofmann</i>	

PART II DNA AS A TOOL TO MODULATE DRUG TARGETS

2 Identification of Aptamers as Specific Binders and Modulators of Cell-Surface Receptor Activity	17
<i>Henning Ulrich and Carsten Wrenger</i>	
3 The Design and Structure–Functional Properties of DNA-Based Immunomodulatory Sequences	41
<i>Nikolai V. Kuznetsov</i>	

PART III RNA INTERFERENCE: FROM DESIGN TO DATA ANALYSIS

4 siRNA Design Principles and Off-Target Effects	59
<i>Sebastian Petri and Gunter Meister</i>	
5 Western Blot Evaluation of siRNA Delivery by pH-Responsive Peptides	73
<i>Wanling Liang, A. James Mason, and Jenny K.W. Lam</i>	
6 High-Throughput RNAi Screening for the Identification of Novel Targets	89
<i>Meredith C. Henderson and David O. Azorsa</i>	
7 Integration of RNAi and Small Molecule Screens to Identify Targets for Drug Development	97
<i>Konstantinos Drosopoulos and Spiros Linardopoulos</i>	
8 CellProfiler and KNIME: Open Source Tools for High Content Screening	105
<i>Martin Stöter, Antje Niederlein, Rico Barsacchi, Felix Meyenhofer, Holger Brandl, and Marc Bickle</i>	
9 PARP Inhibition as a Prototype for Synthetic Lethal Screens	123
<i>Xuesong Liu</i>	

PART IV PROTEIN-FOCUSED TECHNOLOGIES

- 10 Structure-Based Target Druggability Assessment 141
Jean-Yves Trosset and Nicolas Vodovar
- 11 Validating Pharmacological Disruption of Protein–Protein Interactions
by Acceptor Photobleaching FRET Imaging 165
Janos Roszik, Gábor Tóth, János Szöllösi, and György Vereb
- 12 Systematic Analysis of Complex Signal Transduction Pathways
Using Protein Fragment Complementation Assays 179
Thomas I. Koblizek, Ann Siehoff, and Anthony Pitt
- 13 Reverse Phase Protein Microarrays and Their Utility in Drug
Development 187
*Maria Isabella Sereni, Mariaelena Pierobon, Roberto Angioli,
Emanuel F. Petricoin III, and Mitchell J. Frederick*

PART V INNOVATIVE CELL CULTURE TECHNIQUES TO MIMIC TISSUE MICROENVIRONMENTS

- 14 A Cell Culture System That Mimics Chronic Lymphocytic Leukemia
Cells Microenvironment for Drug Screening and Characterization 217
Alessandro Natoni, Michael O'Dwyer, and Corrado Santocanale
- 15 Two-Dimensional vs. Three-Dimensional In Vitro Tumor Migration
and Invasion Assays 227
Miriam Zimmermann, Carol Box, and Suzanne A. Eccles
- 16 Tumor Spheroid-Based Migration Assays for Evaluation
of Therapeutic Agents 253
*Maria Vinci, Carol Box, Miriam Zimmermann,
and Suzanne A. Eccles*
- 17 The Neurosphere Assay Applied to Neural Stem Cells
and Cancer Stem Cells 267
Rossella Galli

PART VI GENETICALLY ENGINEERED ANIMAL MODELS TO STUDY GENE FUNCTIONS

- 18 Genetically Engineered Animal Models for In Vivo Target
Identification and Validation in Oncology 281
Gemma Texidó
- 19 Target Validation in Mice by Constitutive and Conditional RNAi 307
Aljoscha Kleinhammer, Wolfgang Wurst, and Ralf Kühn
- 20 In Vivo Target Validation by Inducible RNAi in Human
Xenograft Mouse Models 325
Marco Mazzeletti and Gemma Texidó

PART VII TRANSLATIONAL METHODS TO VALIDATE BIOMARKERS

21	Bright-Field In Situ Hybridization Methods to Discover Gene Amplifications and Rearrangements in Clinical Samples	341
	<i>Hiroaki Nitta and Thomas M. Grogan</i>	
22	Combined MicroRNA In Situ Hybridization and Immunohistochemical Detection of Protein Markers	353
	<i>Boye Schnack Nielsen and Kim Holmström</i>	
	<i>Index</i>	367

Target Identification and Validation in Drug Discovery

Methods and Protocols

Moll, J.; Colombo, R. (Eds.)

2013, XV, 371 p., Hardcover

ISBN: 978-1-62703-310-7

A product of Humana Press